ストックスクリーナーアプリを入手
18.24
7.29%
1.24
アフターアワーズ：
18.23
-0.010
-0.05%
前日終値:
$17.00
開ける：
$16.78
24時間の取引高:
3.28M
Relative Volume:
1.63
時価総額：
$1.70B
収益：
$352.57M
当期純損益:
$-143.01M
株価収益率:
-10.08
EPS:
-1.81
ネットキャッシュフロー:
$-153.40M
1週間 パフォーマンス:
+7.29%
1か月 パフォーマンス:
-21.72%
6か月 パフォーマンス:
-21.21%
1年 パフォーマンス:
-23.68%
1日の値動き範囲:
$16.66
$19.48
1週間の範囲:
$16.04
$19.48
52週間の値動き範囲:
$13.53
$35.25
Beam Therapeutics Inc Stock (BEAM) Company Profile
名前
Beam Therapeutics Inc
セクター
電話
857-327-8775
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
BEAM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
18.24 | 1.70B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-03-10 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2025-01-29 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-23 | 開始されました | H.C. Wainwright | Buy |
| 2024-01-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-12-08 | ダウングレード | Jefferies | Buy → Hold |
| 2023-10-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-20 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-12-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-12-13 | 開始されました | Citigroup | Buy |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2022-01-05 | 開始されました | Guggenheim | Buy |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-09-24 | 再開されました | Stifel | Buy |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Redburn | Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-03-01 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2021-02-16 | 開始されました | Wells Fargo | Overweight |
| 2021-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-01-06 | 開始されました | Stifel | Hold |
| 2020-08-05 | 開始されました | William Blair | Outperform |
| 2020-03-02 | 開始されました | Barclays | Overweight |
| 2020-03-02 | 開始されました | JP Morgan | Overweight |
| 2020-03-02 | 開始されました | Jefferies | Buy |
| 2020-03-02 | 開始されました | Wedbush | Outperform |
すべてを表示
Beam Therapeutics Inc (BEAM) 最新ニュース
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday - Benzinga
Recent uptick might appease Beam Therapeutics Inc. (NASDAQ:BEAM) institutional owners after losing 29% over the past year - simplywall.st
How To Trade (BEAM) - news.stocktradersdaily.com
Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last? - MSN
Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Cathie Wood's ARK ETF focuses on Beam Therapeutics, Coinbase stock - Investing.com
Biotech Firm Uncovers Gene Therapy Breakthrough in Portugal - streetwisereports.com
Share Price Appreciation of Biotech Due Over Next Six Months - streetwisereports.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock By Investing.com - Investing.com India
Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease - AOL.com
H.C. Wainwright maintains $80 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics Presents Additional Data for BEAM-302 in - GlobeNewswire
Beam Presents Addl. Data From Phase 1/2 Trial Of BEAM-302 In Alpha-1 Antitrypsin Deficiency - Nasdaq
Breakthrough: New BEAM-302 Data Shows 91% Success Rate in Rare Liver Disease Treatment - Stock Titan
Cathie Wood Just Made A Bold Move—Why She Spent Over $65M On Tesla, Robinhood, And Coinbase 'As The Market Crashed' - Benzinga
Beam Therapeutics executive sells $55,330 in stock By Investing.com - Investing.com South Africa
Beam Therapeutics executive sells $55,330 in stock - Investing.com Australia
Beam Therapeutics’ chief legal officer sells $104,121 in stock By Investing.com - Investing.com Canada
Beam Therapeutics’ chief legal officer sells $104,121 in stock - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock By Investing.com - Investing.com India
Beam Therapeutics CEO John Evans sells $562,684 in stock - Investing.com
Beam Therapeutics president sells $136,418 in stock - Investing.com
Beam Therapeutics Executives Sell Shares for Tax Obligations and Personal Sales - TradingView
7 Top Gene-Editing Stocks to Buy | Investing | U.S. News - Money/ US News
Gene Editing: CRISPR Therapeutics vs. Beam Therapeutics - Securities.io
Beam Therapeutics Becomes Oversold - Nasdaq
Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy? - Yahoo Finance
8 Best Gene-Editing Stocks to Buy - Insider Monkey
Biotech stocks plunge as FDA’s Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard - TradingView
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles - Investing.com Canada
Beam Therapeutics’ SWOT analysis: base editing pioneer faces gene therapy hurdles By Investing.com - Investing.com South Africa
The Zacks Analyst Blog Highlights Illumina, BEAM, Twist Bioscience, Wave Life Sciences and CRISPR Therapeutics - Yahoo Finance
BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance - MSN
Beam Therapeutics (BEAM) Upgraded to Buy by Bank of America on P - GuruFocus
Beam Therapeutics (BEAM) Upgraded by BofA on Promising Genetic T - GuruFocus
B of A Securities Upgrades Beam Therapeutics (BEAM) - MSN
Beam upgraded to Buy at BofA Securities on recent genetic condition treatment - Seeking Alpha
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND By Investing.com - Investing.com South Africa
Beam Therapeutics stock rises after FDA clearance for BEAM-302 IND - Investing.com
This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday - Benzinga
B of A Securities Upgrades Beam Therapeutics (BMV:BEAM) - Nasdaq
Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock - Benzinga
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target - Investing.com Canada
BofA raises Beam Therapeutics stock rating to Buy, sets $42 target By Investing.com - Investing.com South Africa
BofA Securities Upgrades Beam Therapeutics to Buy From Neutral - Marketscreener.com
FDA Clears Beam Therapeutics' (BEAM) Drug for Genetic Disease Tr - GuruFocus
Beam Therapeutics gets trial authorization for its genetic disorder treatment in U.S. - Seeking Alpha
Beam Therapeutics New Drug Application for Alpha-1 Antitrypsin Deficiency Gets FDA Clearance - Marketscreener.com
Beam Therapeutics’ BEAM-302 gains FDA’s nod for AATD treatment trial - Investing.com India
Beam Therapeutics Inc (BEAM) 財務データ
収益
当期純利益
現金流量
EPS
0.15%
4.32%
大文字化:
|
ボリューム (24 時間):